UroGen Pharma Ltd.
URGNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, UroGen Pharma Ltd. (URGN) is listed under Biotechnology. With a market capitalization of $1.40B, it sits in small-cap territory. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Market Cap
$1.40B
Beta
1.59
P/E (TTM)
—
P/E (Fwd)
23.35
EPS (TTM)
$-2.74
EPS (Fwd)
$1.23
ROE
—
ROA
-27.0%
Cash
$140.3M
Total Debt
$197.1M
Free CF
-$109.3M
52W Change
576.6%
Annual Financials
Cash vs Debt
On the balance sheet, URGN has $140.3M in cash with $197.1M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$109.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $64.4M (2022) to $109.8M (2025), reflecting a 71% increase over the period.
UroGen Pharma Ltd.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing URGN.